Pancreatic Cancer Research

ResearcherHouston MethodistActive in the last 2 years

Guangjun Nie

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5040-9793; OpenAlex author ID A5051214456. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
29
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 16

  1. Halting Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Neuron-Inhibitory Liposomes. Co-author DOI 10.1021/acs.nanolett.4c05617↗
  2. Disruption of Super-Enhancers in Activated Pancreatic Stellate Cells Facilitates Chemotherapy and Immunotherapy in Pancreatic Cancer. Last author DOI 10.1002/advs.202308637↗
  3. Dual rectification of metabolism abnormality in pancreatic cancer by a programmed nanomedicine. Last author DOI 10.1038/s41467-024-54963-y↗
  4. Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies. Co-author DOI 10.1016/j.canlet.2023.216138↗
  5. Injectable Immunotherapeutic Hydrogel Containing RNA-Loaded Lipid Nanoparticles Reshapes Tumor Microenvironment for Pancreatic Cancer Therapy. Co-author DOI 10.1021/acs.nanolett.2c01994↗
  6. Tailor-Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202002545↗
  7. Penetration Cascade of Size Switchable Nanosystem in Desmoplastic Stroma for Improved Pancreatic Cancer Therapy. Last author DOI 10.1021/acsnano.0c08860↗
  8. Co-Delivery of Gemcitabine and Mcl-1 SiRNA via Cationic Liposome-Based System Enhances the Efficacy of Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1166/jbn.2019.2762↗
  9. Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment. Co-author DOI 10.1016/j.biomaterials.2017.12.015↗
  10. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment. Last author DOI 10.1016/j.canlet.2018.05.042↗
  11. Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer … Co-author DOI 10.1021/acsnano.8b01573↗
  12. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. Last author DOI 10.1016/j.canlet.2017.05.015↗
  13. Photothermal Effect Enhanced Cascade-Targeting Strategy for Improved Pancreatic Cancer Therapy by Gold Nanoshell@Mesoporous Silica Nanorod. Last author DOI 10.1021/acsnano.7b02918↗
  14. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Last author DOI 10.1016/j.biomaterials.2016.06.032↗
  15. An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer. Last author DOI 10.1021/acsami.5b11619↗
  16. Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer. Co-author DOI 10.1016/j.biomaterials.2014.12.028↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yiye Li · 7 shared papers, 2015–2025 · strength 1.01
  2. Zhiqin Wang · 3 shared papers, 2023–2025 · strength 0.70
  3. Xiao Zhao · 6 shared papers, 2017–2022 · strength 0.59
  4. Bowen Wu · 2 shared papers, 2023–2024 · strength 0.43
  5. He Ren · 4 shared papers, 2015–2022 · strength 0.34
  6. Xudong Wang · 2 shared papers, 2021–2024 · strength 0.32
  7. Jihui Hao · 5 shared papers, 2015–2018 · strength 0.28
  8. Yinmo Yang · 2 shared papers, 2018–2024 · strength 0.27
  9. Chong Du · 2 shared papers, 2018–2024 · strength 0.27
  10. Ruifang Zhao · 4 shared papers, 2016–2018 · strength 0.25
  11. Xiao Ling Zhao · 4 shared papers, 2015–2018 · strength 0.22
  12. Yazhou Wang · 1 shared paper, 2024 · strength 0.20
  13. Kai Chen · 1 shared paper, 2024 · strength 0.20
  14. Tianjiao Ji · 3 shared papers, 2016–2017 · strength 0.18
  15. Chao Gao · 1 shared paper, 2022 · strength 0.17
  16. Ruining Gong · 1 shared paper, 2022 · strength 0.17
  17. Xiuchao Wang · 3 shared papers, 2016–2018 · strength 0.17
  18. Xi Hu · 1 shared paper, 2021 · strength 0.14
  19. Daishun Ling · 1 shared paper, 2021 · strength 0.14
  20. Hai Wang · 2 shared papers, 2015–2017 · strength 0.13
  21. Xiaozheng Zhao · 1 shared paper, 2021 · strength 0.13
  22. Yongwei Wang · 2 shared papers, 2017–2018 · strength 0.12
  23. Qun Tao Yu · 1 shared paper, 2019 · strength 0.09
  24. Yanbing Wang · 1 shared paper, 2019 · strength 0.09
  25. Yuliang Zhao · 1 shared paper, 2017 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.